

Pulmonary Hypertension Drugs Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

<https://marketpublishers.com/r/P50C504EEE72EN.html>

Date: December 2020

Pages: 95

Price: US\$ 3,000.00 (Single User License)

ID: P50C504EEE72EN

Abstracts

SUMMARY

Further key aspects of the report indicate that:

Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology

Chapter 2: Global Industry Summary

Chapter 3: Market Dynamics

Chapter 4: Global Market Segmentation by region, type and End-Use

Chapter 5: North America Market Segmentation by region, type and End-Use

Chapter 6: Europe Market Segmentation by region, type and End-Use

Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use

Chapter 8: South America Market Segmentation by region, type and End-Use

Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.

Chapter 10: Market Competition by Companies

Chapter 11: Market forecast and environment forecast.

Chapter 12: Industry Summary.

The global Pulmonary Hypertension Drugs market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Pulmonary Hypertension Drugs market segmented into

Prostacyclin and prostacyclin analogs

Endothelin receptor antagonists (ERAs)

Phosphodiesterase-5 (PDE-5) inhibitors

Soluble guanylate cyclase (sGC) stimulators

Based on the end-use, the global Pulmonary Hypertension Drugs market classified into

Early-stage Drug Candidates (Phase I & Phase II)

Late-stage Drug Candidates (Phase III & Registration Phase)

Based on geography, the global Pulmonary Hypertension Drugs market segmented into

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are

Bayer

GSK

Arena

Actelion

Pfizer

United Therapeutics

Gilead Sciences

Lung Biotechnology PBC

Contents

1 RESEARCH SCOPE

- 1.1 Research Product Definition
- 1.2 Research Segmentation
 - 1.2.1 Product Type
 - 1.2.2 Main product Type of Major Players
- 1.3 Demand Overview
- 1.4 Research Methodology

2 GLOBAL PULMONARY HYPERTENSION DRUGS INDUSTRY

- 2.1 Summary about Pulmonary Hypertension Drugs Industry
- 2.2 Pulmonary Hypertension Drugs Market Trends
 - 2.2.1 Pulmonary Hypertension Drugs Production & Consumption Trends
 - 2.2.2 Pulmonary Hypertension Drugs Demand Structure Trends
- 2.3 Pulmonary Hypertension Drugs Cost & Price

3 MARKET DYNAMICS

- 3.1 Manufacturing & Purchasing Behavior in 2020
- 3.2 Market Development under the Impact of COVID-19
 - 3.2.1 Drivers
 - 3.2.2 Restraints
 - 3.2.3 Opportunity
 - 3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

- 4.1 Region Segmentation (2017 to 2021f)
 - 4.1.1 North America (U.S., Canada and Mexico)
 - 4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
 - 4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
 - 4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
 - 4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
- 4.2 Product Type Segmentation (2017 to 2021f)

- 4.2.1 Prostacyclin and prostacyclin analogs
- 4.2.2 Endothelin receptor antagonists (ERAs)
- 4.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
- 4.2.4 Soluble guanylate cyclase (sGC) stimulators
- 4.3 Consumption Segmentation (2017 to 2021f)
 - 4.3.1 Early-stage Drug Candidates (Phase I & Phase II)
 - 4.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)

5 NORTH AMERICA MARKET SEGMENT

- 5.1 Region Segmentation (2017 to 2021f)
 - 5.1.1 U.S.
 - 5.1.2 Canada
 - 5.1.3 Mexico
- 5.2 Product Type Segmentation (2017 to 2021f)
 - 5.2.1 Prostacyclin and prostacyclin analogs
 - 5.2.2 Endothelin receptor antagonists (ERAs)
 - 5.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
 - 5.2.4 Soluble guanylate cyclase (sGC) stimulators
- 5.3 Consumption Segmentation (2017 to 2021f)
 - 5.3.1 Early-stage Drug Candidates (Phase I & Phase II)
 - 5.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
- 5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

- 6.1 Region Segmentation (2017 to 2021f)
 - 6.1.1 Germany
 - 6.1.2 UK
 - 6.1.3 France
 - 6.1.4 Italy
 - 6.1.5 Rest of Europe
- 6.2 Product Type Segmentation (2017 to 2021f)
 - 6.2.1 Prostacyclin and prostacyclin analogs
 - 6.2.2 Endothelin receptor antagonists (ERAs)
 - 6.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
 - 6.2.4 Soluble guanylate cyclase (sGC) stimulators
- 6.3 Consumption Segmentation (2017 to 2021f)
 - 6.3.1 Early-stage Drug Candidates (Phase I & Phase II)

- 6.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
- 6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

- 7.1 Region Segmentation (2017 to 2021f)
 - 7.1.1 China
 - 7.1.2 India
 - 7.1.3 Japan
 - 7.1.4 South Korea
 - 7.1.5 Southeast Asia
 - 7.1.6 Australia
 - 7.1.7 Rest of Asia Pacific
- 7.2 Product Type Segmentation (2017 to 2021f)
 - 7.2.1 Prostacyclin and prostacyclin analogs
 - 7.2.2 Endothelin receptor antagonists (ERAs)
 - 7.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
 - 7.2.4 Soluble guanylate cyclase (sGC) stimulators
- 7.3 Consumption Segmentation (2017 to 2021f)
 - 7.3.1 Early-stage Drug Candidates (Phase I & Phase II)
 - 7.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
- 7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

- 8.1 Region Segmentation (2017 to 2021f)
 - 8.1.1 Brazil
 - 8.1.2 Argentina
 - 8.1.3 Rest of Latin America
- 8.2 Product Type Segmentation (2017 to 2021f)
 - 8.2.1 Prostacyclin and prostacyclin analogs
 - 8.2.2 Endothelin receptor antagonists (ERAs)
 - 8.2.3 Phosphodiesterase-5 (PDE-5) inhibitors
 - 8.2.4 Soluble guanylate cyclase (sGC) stimulators
- 8.3 Consumption Segmentation (2017 to 2021f)
 - 8.3.1 Early-stage Drug Candidates (Phase I & Phase II)
 - 8.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)
- 8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Prostacyclin and prostacyclin analogs

9.2.2 Endothelin receptor antagonists (ERAs)

9.2.3 Phosphodiesterase-5 (PDE-5) inhibitors

9.2.4 Soluble guanylate cyclase (sGC) stimulators

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Early-stage Drug Candidates (Phase I & Phase II)

9.3.2 Late-stage Drug Candidates (Phase III & Registration Phase)

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Bayer

10.1.2 GSK

10.1.3 Arena

10.1.4 Actelion

10.1.5 Pfizer

10.1.6 United Therapeutics

10.1.7 Gilead Sciences

10.1.8 Lung Biotechnology PBC

10.2 Pulmonary Hypertension Drugs Sales Date of Major Players (2017-2020e)

10.2.1 Bayer

10.2.2 GSK

10.2.3 Arena

10.2.4 Actelion

10.2.5 Pfizer

10.2.6 United Therapeutics

10.2.7 Gilead Sciences

10.2.8 Lung Biotechnology PBC

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

List Of Tables

LIST OF TABLES

- Table Pulmonary Hypertension Drugs Product Type Overview
- Table Pulmonary Hypertension Drugs Product Type Market Share List
- Table Pulmonary Hypertension Drugs Product Type of Major Players
- Table Brief Introduction of Bayer
- Table Brief Introduction of GSK
- Table Brief Introduction of Arena
- Table Brief Introduction of Actelion
- Table Brief Introduction of Pfizer
- Table Brief Introduction of United Therapeutics
- Table Brief Introduction of Gilead Sciences
- Table Brief Introduction of Lung Biotechnology PBC
- Table Products & Services of Bayer
- Table Products & Services of GSK
- Table Products & Services of Arena
- Table Products & Services of Actelion
- Table Products & Services of Pfizer
- Table Products & Services of United Therapeutics
- Table Products & Services of Gilead Sciences
- Table Products & Services of Lung Biotechnology PBC
- Table Market Distribution of Major Players
- Table Global Major Players Sales Revenue (Million USD) 2017-2020e
- Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
- Table Global Pulmonary Hypertension Drugs Market Forecast (Million USD) by Region 2021f-2026f
- Table Global Pulmonary Hypertension Drugs Market Forecast (Million USD) Share by Region 2021f-2026f
- Table Global Pulmonary Hypertension Drugs Market Forecast (Million USD) by Demand 2021f-2026f
- Table Global Pulmonary Hypertension Drugs Market Forecast (Million USD) Share by Demand 2021f-2026f

List Of Figures

LIST OF FIGURES

- Figure Global Pulmonary Hypertension Drugs Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
- Figure Global Pulmonary Hypertension Drugs Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
- Figure Global Pulmonary Hypertension Drugs Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
- Figure Global Pulmonary Hypertension Drugs Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
- Figure Global Pulmonary Hypertension Drugs Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
- Figure Global Pulmonary Hypertension Drugs Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
- Figure Global Pulmonary Hypertension Drugs Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
- Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- Figure Prostacyclin and prostacyclin analogs Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- Figure Endothelin receptor antagonists (ERAs) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- Figure Phosphodiesterase-5 (PDE-5) inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- Figure Soluble guanylate cyclase (sGC) stimulators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- Figure Early-stage Drug Candidates (Phase I & Phase II) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
- Figure Late-stage Drug Candidates (Phase III & Registration Phase) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%)

2018-2021f

Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Prostacyclin and prostacyclin analogs Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Endothelin receptor antagonists (ERAs) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Phosphodiesterase-5 (PDE-5) inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Soluble guanylate cyclase (sGC) stimulators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Early-stage Drug Candidates (Phase I & Phase II) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Late-stage Drug Candidates (Phase III & Registration Phase) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Prostacyclin and prostacyclin analogs Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Endothelin receptor antagonists (ERAs) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Phosphodiesterase-5 (PDE-5) inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Soluble guanylate cyclase (sGC) stimulators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Early-stage Drug Candidates (Phase I & Phase II) Segmentation Market Size

(USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Late-stage Drug Candidates (Phase III & Registration Phase) Segmentation
Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%)
2018-2021f
Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth
(%) 2018-2021f
Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth
(%) 2018-2021f
Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth
(%) 2018-2021f
Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY)
Growth (%) 2018-2021f
Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY)
Growth (%) 2018-2021f
Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY)
Growth (%) 2018-2021f
Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year
(YOY) Growth (%) 2018-2021f
Figure Prostacyclin and prostacyclin analogs Segmentation Market Size (USD Million)
2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Endothelin receptor antagonists (ERAs) Segmentation Market Size (USD
Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Phosphodiesterase-5 (PDE-5) inhibitors Segmentation Market Size (USD
Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Soluble guanylate cyclase (sGC) stimulators Segmentation Market Size (USD
Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Early-stage Drug Candidates (Phase I & Phase II) Segmentation Market Size
(USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Late-stage Drug Candidates (Phase III & Registration Phase) Segmentation
Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%)
2018-2021f
Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth
(%) 2018-2021f
Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY)
Growth (%) 2018-2021f
Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year
(YOY) Growth (%) 2018-2021f
Figure Prostacyclin and prostacyclin analogs Segmentation Market Size (USD Million)
2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Endothelin receptor antagonists (ERAs) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Phosphodiesterase-5 (PDE-5) inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Soluble guanylate cyclase (sGC) stimulators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Early-stage Drug Candidates (Phase I & Phase II) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Late-stage Drug Candidates (Phase III & Registration Phase) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Prostacyclin and prostacyclin analogs Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Endothelin receptor antagonists (ERAs) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Phosphodiesterase-5 (PDE-5) inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Soluble guanylate cyclase (sGC) stimulators Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Early-stage Drug Candidates (Phase I & Phase II) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Late-stage Drug Candidates (Phase III & Registration Phase) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Pulmonary Hypertension Drugs Sales Revenue (Million USD) of Bayer 2017-2020e

Figure Pulmonary Hypertension Drugs Sales Revenue (Million USD) of GSK 2017-2020e

Figure Pulmonary Hypertension Drugs Sales Revenue (Million USD) of Arena 2017-2020e

Figure Pulmonary Hypertension Drugs Sales Revenue (Million USD) of Actelion

2017-2020e

Figure Pulmonary Hypertension Drugs Sales Revenue (Million USD) of Pfizer

2017-2020e

Figure Pulmonary Hypertension Drugs Sales Revenue (Million USD) of United Therapeutics 2017-2020e

Figure Pulmonary Hypertension Drugs Sales Revenue (Million USD) of Gilead Sciences 2017-2020e

Figure Pulmonary Hypertension Drugs Sales Revenue (Million USD) of Lung Biotechnology PBC 2017-2020e

I would like to order

Product name: Pulmonary Hypertension Drugs Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Product link: <https://marketpublishers.com/r/P50C504EEE72EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P50C504EEE72EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

